Canaccord notes that the U.S. House of Representatives passed a draft of the BIOSECURE Act with bipartisan support, noting that the “relatively controversial” bill would essentially require U.S. life sciences customers to end their relationships with Chinese companies, including sequencing companies and contract manufacturers, by 2032. If the bill is passed, this would be a “modest positive” for Illumina (ILMN) and PacBio (PACB), said the analyst, who adds that Illumina would continue to face headwinds in China and that it remains unclear if the Senate will take up the House version of the BIOSECURE Act or a different version.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina Strategically Manages Debt and Issues New Notes
- Jefferies healthcare analyst holds an analyst/industry conference call
- Illumina files automatic mixed securities shelf
- ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
- Illumina Wins EU Top Court’s Support in Grail Acquisition